Transtympanic Micropressure Applications as a Treatment of Meniere's Disease
This policy governs coverage and medical necessity determinations for transtympanic micropressure applications (Meniett device) as a treatment for Meniere's disease for Blue Cross Blue Shield - Rhode Island members.
No material clinical or coverage changes in this revision.
Coverage Determinations
Not Medically Necessary / Not Covered
Covered when ALL of the following are met:
Evidence summary: Six randomized controlled trials (five specifically of the Meniett device) and systematic reviews found no greater reduction in vertigo or other benefit compared with placebo; the technology is unlikely to improve net health outcome.
Transtympanic micropressure applications (Meniett device) for the treatment of Meniere's disease are not covered / considered not medically necessary. The evidence is insufficient to determine the effects of this technology on health outcomes.
For Commercial Products, transtympanic micropressure applications are considered not medically necessary because available evidence does not demonstrate benefit. For Medicare Advantage Plans, the associated device code E2120 (pulse generator system for tympanic treatment of inner ear endolymphatic fluid) is considered not covered.
Coding and Billing
| E2120 | Pulse generator system for tympanic treatment of inner ear endolymphatic fluid |
Provider Actions and Billing Guidance
Prior authorization
Prior authorization: Not applicable. Providers should verify member-specific benefits and any prior authorization requirements with the applicable Benefit Booklet, Evidence of Coverage, or Subscriber Agreement before providing services.
- Check member-specific coverage and prior authorization requirements in the Benefit Booklet, Evidence of Coverage, or Subscriber Agreement.
Conservative therapy context
Conservative (non-surgical) therapies are considered standard initial management for Meniere’s disease and should be attempted prior to interventional or surgical options. These conservative measures include a low‑sodium diet, diuretics (to reduce endolymphatic fluid accumulation), and pharmacologic therapies to control vestibular symptoms. For patients who do not respond to these measures, intratympanic gentamicin (chemical labyrinthectomy) may be used to ablate vestibular function on the affected side. Transtympanic micropressure therapy (e.g., Meniett) is an alternative approach under investigation that delivers intermittent low‑frequency, low‑amplitude pressure pulses to the middle ear; however, evidence is insufficient to establish benefit.
- Conservative therapies: low‑sodium diet, diuretics, vestibular symptom control medications.
- If conservative therapy fails, options may include intratympanic gentamicin for chemical labyrinthectomy.
Denial risk for Meniett therapy
Claims for transtympanic micropressure therapy (Meniett) and the pulse generator device are considered not covered / not medically necessary per this policy. Providers should expect claim denials for the device E2120 and related transtympanic micropressure treatment for Meniere’s disease.
Benefit verification
Verify benefits and eligibility for each member before providing services. Benefit documents (Benefit Booklet, Evidence of Coverage, Subscriber Agreement) determine coverage and supersede this medical policy. Contact the provider call center for member-specific information.
- Confirm whether transtympanic micropressure therapy or related devices are covered for the member's contract prior to treatment.
- If services are non-covered and the provider proceeds, obtain written agreement from the member regarding payment responsibility as required by your participation agreement.
Background
Meniere's disease is an idiopathic inner ear disorder characterized by episodic vertigo, fluctuating hearing loss, tinnitus, and aural pressure. Conservative management commonly includes dietary sodium restriction, diuretics, and pharmacologic control of vestibular symptoms; transtympanic micropressure therapy (Meniett) delivers intermittent air-pressure pulses through a tympanostomy tube and is typically self-administered for short sessions several times daily.
Definitions
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.